233 results on '"Papa, Sophie"'
Search Results
2. Acute kidney injury in patients treated with immune checkpoint inhibitors
3. Pre-treatment with systemic agents for advanced NSCLC elicits changes in the phenotype of autologous T cell therapy products
4. A call to adapt the regulation of HLA testing for T cell receptor-based therapeutics
5. Circulating inflammatory proteins associate with response to immune checkpoint inhibition therapy in patients with advanced melanoma
6. Association between COVID-19 burden and delays to diagnosis and treatment of cancer patients in England
7. Differences between immunotherapy-induced and primary hypophysitis—a multicenter retrospective study
8. Regulatory B cell repertoire defects predispose lung cancer patients to immune-related toxicity following checkpoint blockade
9. Germline genetic variation and predicting immune checkpoint inhibitor induced toxicity
10. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study
11. Acute Immune Signatures and Their Legacies in Severe Acute Respiratory Syndrome Coronavirus-2 Infected Cancer Patients
12. British Society of Gastroenterology endorsed guidance for the management of immune checkpoint inhibitor-induced enterocolitis
13. Lifileucel, an Autologous Tumor-infiltrating Lymphocyte Monotherapy, in Patients with Advanced Non-small Cell Lung Cancer Resistant to Immune Checkpoint Inhibitors
14. Metabolic armouring of CAR and TCR T cells
15. A Retrospective Chart Review Study of Real-World Use of Talimogene Laherparepvec in Unresectable Stage IIIB–IVM1a Melanoma in Four European Countries
16. IgE re-programs alternatively-activated human macrophages towards pro-inflammatory anti-tumoural states
17. A call to adapt the regulation of HLA testing for T cell receptor-based therapeutics
18. 362 Allelic variants of MR1 drive cancer and allo-reactivity by MR1-restricted T cells
19. Provision of cancer care during the COVID-19 pandemic
20. Optimal selection of tumor antigens
21. Conserved allomorphs of MR1 drive specificity of MR1-restricted TCRs
22. Intratumoral pan-ErbB targeted CAR-T for head and neck squamous cell carcinoma: interim analysis of the T4 immunotherapy study
23. The threat of triple M and autoimmune overlap syndromes with immune checkpoint inhibitors - A series of case reports
24. Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine, prophylactic radiotherapy, and systemic chemotherapy in patients with malignant pleural mesothelioma: A 10-year experience
25. A rapidly expanding cutaneous tumour in the context of a Janus kinase inhibitor agent following allogeneic stem cell transplant
26. Papulonodular pigmented lesions in a patient with Stage IV malignant melanoma
27. Oral beclomethasone dipropionate is an effective treatment for immune checkpoint inhibitor induced colitis
28. Safe delivery of systemic anti‐cancer treatment for skin cancers during the COVID ‐19 pandemic
29. 18F FDG PET/CT and Novel Molecular Imaging for Directing Immunotherapy in Cancer
30. Phase 2 Study of Sorafenib in Malignant Mesothelioma Previously Treated with Platinum-Containing Chemotherapy
31. CDK Inhibition Primes for Anti-PD-L1 Treatment in Triple-Negative Breast Cancer Models
32. Immune checkpoint inhibitor‐related cholangiopathy: Novel clinicopathological description of a multi‐centre cohort
33. BRAF inhibitors and their immunological effects in malignant melanoma
34. Humoral and cellular immunity to delayed second dose of SARS-CoV-2 BNT162b2 mRNA vaccination in patients with cancer
35. The Impact of COVID-19 on the Delivery of Systemic Anti-Cancer Treatment at Guy’s Cancer Centre
36. Understanding the Lived Experiences of Patients With Melanoma: Real-World Evidence Generated Through a European Social Media Listening Analysis (Preprint)
37. PMO-47 Clipper (Beclomethasone Dipropionate) as a treatment for checkpoint inhibitor induced enterocolitis
38. 458 First phase 2 results of autologous tumor-infiltrating lymphocyte (TIL; LN-145) monotherapy in patients with advanced, immune checkpoint inhibitor-treated, non-small cell lung cancer (NSCLC)
39. ATU-2 A multi-centre study of Infliximab treatment for corticosteroid-refractory Checkpoint Inhibitor Induced enterocolitis
40. Safe delivery of systemic anti‐cancer treatment for skin cancers during the COVID‐19 pandemic.
41. Immune checkpoint inhibitor‐related cholangiopathy: Novel clinicopathological description of a multi‐centre cohort.
42. Clinical Evaluation of ErbB-Targeted CAR T-Cells, Following Intracavity Delivery in Patients with ErbB-Expressing Solid Tumors
43. Differences between immunotherapy-induced and primary hypophysitis—a multicenter retrospective study
44. Development and Validation of a Good Manufacturing Process for IL-4-Driven Expansion of Chimeric Cytokine Receptor-Expressing CAR T-Cells
45. Clinical outcomes of patients with corticosteroid refractory immune checkpoint inhibitor-induced enterocolitis treated with infliximab
46. Abstract LB076: Association between regional COVID-19 hospitalizations and treatment delays amongst confirmed cancer patients in England, UK
47. Immunotherapy using IgE or CAR T cells for cancers expressing the tumor antigen SLC3A2
48. COVID-19 Risk Factors for Cancer Patients: A First Report with Comparator Data from COVID-19 Negative Cancer Patients
49. 108 INFLIXIMAB TREATMENT FOR CHECKPOINT INHIBITOR INDUCED COLITIS: CLINICAL OUTCOMES FROM A MULTI-CENTRE STUDY
50. Interim results of the safety and immune-efficacy of 1 versus 2 doses of COVID-19 vaccine BNT162b2 for cancer patients in the context of the UK vaccine priority guidelines
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.